$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR $(R)$
$17 million in cash and cash equivalents as of June 30, 2026
Expanded LYMPHIR commercial and medical affairs organizations deployed nationwide
CRANFORD, N.J., Aug. 14, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for the fiscal third quarter ended June 30, 2026, and provided a business update, including progress at its majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR).
"The LYMPHIR launch continued to build momentum in our fiscal third quarter and remains the primary driver of our business. The number of institutional vial orders increased, new institutions placed orders, and LYMPHIR became available at 44 leading academic oncology centers, NCCN institutions and community infusion centers. These indicators demonstrate meaningful progress in formulary access and treatment-driven demand as physicians gain familiarity with LYMPHIR's differentiated clinical profile," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Pharma and Citius Oncology.
"Following the quarter end, we completed the nationwide deployment of Citius Oncology's expanded commercial and medical affairs teams, which now total 29 professionals. These teams are positioned to leverage the existing platform established to support LYMPHIR's success, including patient hub services, marketing, reimbursement support, and market access. We believe our expanded organization will facilitate increased engagement with priority treatment centers, support formulary adoption and broaden access for eligible patients as the launch matures," added Mazur.
"We also continued to advance LYMPHIR's longer-term value proposition. Phase 1 investigator-initiated data presented at ASCO demonstrated encouraging clinical activity and durable responses for LYMPHIR in combination with pembrolizumab in heavily pre-treated gynecologic malignancies. Additionally, Phase 1 data of LYMPHIR administered prior to CAR-T therapy in high-risk relapsed or refractory DLBCL, presented at the 2026 ASTCT(R) & CIBMTR(R) Tandem Meetings, showed an 86% objective response rate, including 57% complete response, with no dose-limiting toxicities observed. These positive signals point to LYMPHIR's potential beyond cutaneous T-cell lymphoma. As we scale, we remain focused on disciplined execution and building the long-term sustainable value of LYMPHIR," concluded Mazur.
Fiscal Third Quarter 2026 Business Highlights and Subsequent Developments
-- Continued commercial momentum for LYMPHIR, with availability in 44
institutions, including academic oncology centers, leading National
Comprehensive Cancer Network (NCCN) institutions and community infusion
centers;
-- Increased the number of new institutions ordering LYMPHIR by 80% and grew
institutional vial orders from wholesalers by 31%;
-- Drove continued institutional demand growth in July, with 383 vials
ordered by institutions from wholesalers, the largest vial order month to
date;
-- Secured near universal payer coverage, with no reimbursement denials or
preauthorization barriers reported to date;
-- Expanded Citius Oncology's commercial organization by 21 commercial
field-based professionals and added eight medical science liaisons, with
nationwide deployment completed in August 2026 through EVERSANA, the
Company's exclusive commercialization partner;
-- Advanced Phase 1 investigator-initiated trials:
-- Data were presented at the 2026 American Society of Clinical
Oncology (ASCO) Annual Meeting evaluating LYMPHIR in combination
with pembrolizumab in recurrent or refractory gynecologic
malignancies:
-- 24% overall response rate $(ORR)$ and a 48% clinical benefit
rate, and
-- median progression-free survival of 20.5 months among
patients achieving clinical benefit;
-- Data were presented at the 2026 ASTCT(R) & CIBMTR(R) Tandem
Meetings evaluating LYMPHIR administered prior to CAR-T therapy in
high-risk relapsed or refractory diffuse large B-cell lymphoma
(DLBCL):
-- 86% ORR, including 57% complete response $(CR)$ and 29%
partial response $(PR)$,
-- LYMPHIR was well-tolerated with no dose-limiting toxicities
observed;
-- Closed a registered direct offering in April 2026 for net proceeds of
approximately $4.5 million;
-- Received approximately $9.7 million in net proceeds from the exercise of
certain warrants and funded $10.0 million under the first tranche of a
Citius Oncology senior secured term loan facility of up to $25.0 million;
and,
-- Citius Oncology appointed Jonathan Peri, Ph.D., J.D., as an independent
director, effective August 10, 2026, expanding the board to nine members.
Fiscal Third Quarter 2026 Financial Highlights and Subsequent Developments
-- Cash and cash equivalents of $17.0 million as of June 30, 2026;
-- Revenues of $1.5 million for the three months ended June 30, 2026,
compared with no revenue for the three months ended June 30, 2025; and
$7.1 million for the nine months ended June 30, 2026, compared with no
revenue for the nine months ended June 30, 2025;
-- Gross profit of $1.0 million for the three months ended June 30, 2026,
representing a gross margin of approximately 67%, and $5.5 million for
the nine months ended June 30, 2026, representing a gross margin of
approximately 77%;
-- Research and development expenses of $1.1 million for the three months
ended June 30, 2026, compared with $1.6 million for the three months
ended June 30, 2025; and $4.3 million for the nine months ended June 30,
2026, compared with $7.5 million for the nine months ended June 30, 2025;
-- General and administrative expenses of $6.1 million for the three months
ended June 30, 2026, compared with $4.4 million for the three months
ended June 30, 2025. General and administrative expenses were $38.3
million for the nine months ended June 30, 2026, compared with $14.6
million for the nine months ended June 30, 2025. The nine-month increase
primarily reflects a non-recurring $19.7 million contract cancellation
charge recognized in March 2026 and increased expenses related to the
commercial launch of LYMPHIR;
-- Stock-based compensation expense of $3.8 million for the three months
ended June 30, 2026, compared with $2.7 million for the three months
ended June 30, 2025; and $11.9 million for the nine months ended June 30,
2026, compared with $7.9 million for the nine months ended June 30, 2025;
and,
-- Net loss applicable to common stockholders of $8.9 million, or $(0.34)
per share, for the three months ended June 30, 2026, compared with $8.8
million, or $(0.80) per share, for the three months ended June 30, 2025;
and $38.3 million, or $(1.64) per share, for the nine months ended June
30, 2026, compared with $29.5 million, or $(3.27) per share, for the nine
months ended June 30, 2025.
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately 62% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I--III CTCL who had had at least one prior systemic therapy. Citius Pharma's late-stage pipeline also includes Mino-Lok(R) , a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.
About Citius Oncology, Inc.
Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I--III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.
Forward-Looking Statements
Comments